Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD7 CRISPR/Cas9 KO Plasmid (h): sc-407287
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD7 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD7 Antibody (CBC.37): sc-59108
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD7 CRISPR/Cas9 KO Plasmid (h) | sc-407287 | 20 µg | $397.00 |
Overview
CD7 encodes a transmembrane immunoglobulin superfamily receptor expressed predominantly on thymocytes and mature T cells, where it participates in T cell activation, adhesion, and immunological synapse organization through interactions that modulate signaling thresholds. CD7-associated signaling interfaces with SRC-family kinase and MAPK-linked pathways that shape T cell differentiation, cytokine responses, and cytotoxic effector function. Altered CD7 expression is frequently used as an immunophenotypic feature in lymphoid biology and is studied in the context of T cell malignancy models and immune dysregulation. As a surface marker coupled to functional signaling roles, CD7 provides a tractable node for dissecting T cell receptor–proximal signaling networks and lineage programs.
CD7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CD7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CD7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CD7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD7 protein expression.
This CRISPR knockout system enables efficient generation of CD7-deficient cell models for investigation of CD7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CD7 exon(s) critical for CD7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CD7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD7 CRISPR/Cas9 KO Plasmid (h) and CD7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CD7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD7 HDR Plasmid (h) and CD7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CD7 homology arms to support homology-directed repair at defined CD7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.